Semagacestat
Alzheimer's Disease
Herausgegeben: Eyvindr, Lennox Raphael
Versandkostenfrei!
Versandfertig in 6-10 Tagen
23,99 €
inkl. MwSt.
PAYBACK Punkte
12 °P sammeln!
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Semagacestat (LY450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Élan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients, but in August 2010, a disappointing interim analysis, in which semagacestat performed less well than the placebo, led to investigators being instructed to tell subjects to stop taking the drug. -amyloid is a peptide of 39 to 43 am...
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Semagacestat (LY450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Élan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients, but in August 2010, a disappointing interim analysis, in which semagacestat performed less well than the placebo, led to investigators being instructed to tell subjects to stop taking the drug. -amyloid is a peptide of 39 to 43 amino acids. The isoforms with 40 and 42 amino acids (A 40/42) are the main constituents of amyloid plaques in the brains of Alzheimer's disease patients. -amyloid is formed by proteolysis of APP. Research on laboratory rats suggest that the soluble form of this peptide is a causative agent in the development of Alzheimer's.
Andere Kunden interessierten sich für
